WHY COLLECT REAL WORLD DATA IN AN EXPANDED ACCESS PROGRAM?
Expanded Access Programs (EAPs) provide sponsors the opportunity to collect meaningful Real World Data (RWD), i.e. data on health care that is derived from multiple sources outside of the typical clinical research settings.
More and more, regulatory bodies around the world, like the US Food and Drug Administration (FDA), European Medicines Agency (EMA) and the Australian Therapeutic Goods Administration (TGA), etc. are encouraging companies to collect RWD, if and when appropriate. These regulators recognize the tremendous value in collecting data in the real world setting and using it to better inform stakeholders and promote safe and effective use of products, quicker, for patients in need.
WEP Clinical has developed some slides to help companies better understand RWD collection in the expanded access space.
The slides will explore the following:
What is RWD
Sponsor and HCPs Considerations
Why collect RWD in EAPs
Types of data to collect
Regulations and examples
Regulations and examples
EDC system capabilities
To find out more about our RWD collection capabilities, please contact us using the email address below:
download Slides
Please provide your name and email address in the fields below and press the download button. You should then receive the slides as a pdf in a new tab in your browser.